Article
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
Pharmacogenomics - 1 Feb 2011
Lemos Clara, Giovannetti Elisa, Zucali Paolo A, Assaraf Yehuda G, Scheffer George L, van der Straaten Tahar, D'Incecco Armida, Falcone Alfredo, Guchelaar Henk-Jan, Danesi Romano, Santoro Armando, Giaccone Giuseppe, Tibaldi Carmelo, Peters Godefridus J
Abstract excerpt
AIMS: The current study investigates whether or not functional polymorphisms in the ATP-binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non-small-cell lung cancer (NSCLC) patients. MATERIALS & METHODS: Towards this end, ABCG2 polymorphisms and expression were assessed in DNA and tumors from 94 NSCLC patients treated with gefitinib, whereas their associations with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
